KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 14,400 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 14,400 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the completion of the transaction, the chief executive officer now directly owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. This trade represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $8.96 on Thursday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.39 and a 12-month high of $16.88. The stock’s 50-day moving average price is $11.06 and its two-hundred day moving average price is $12.01.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. Analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KALV has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. Finally, Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vestal Point Capital LP boosted its holdings in KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after acquiring an additional 1,700,000 shares during the last quarter. Capital World Investors purchased a new position in shares of KalVista Pharmaceuticals in the 1st quarter worth about $17,370,000. Great Point Partners LLC acquired a new position in shares of KalVista Pharmaceuticals in the 2nd quarter valued at about $15,768,000. State Street Corp lifted its stake in shares of KalVista Pharmaceuticals by 68.1% in the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after purchasing an additional 515,179 shares in the last quarter. Finally, Emerald Advisers LLC increased its position in KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).